Do Not Add Amantadine to This Regimen
Amantadine is not recommended for binge-eating disorder and has no evidence base for this indication. The patient is already on an evidence-based regimen with lisdexamfetamine and a GLP-1 agonist, and adding amantadine would introduce unnecessary risk without proven benefit.
Why Amantadine Should Not Be Added
Lack of Evidence for BED
- No guideline support: The 2023 APA guidelines for eating disorders make no mention of amantadine as a treatment option for binge-eating disorder 1111
- No research evidence: Among the available evidence, there are no studies examining amantadine's efficacy for BED
- Off-label use without rationale: Unlike the medications with established roles in BED, amantadine has no mechanistic or clinical justification for this indication
Current Regimen Is Already Evidence-Based
The patient is on two medications with actual evidence for BED:
Lisdexamfetamine (Vyvanse):
- APA suggests (2C) that adults with BED who prefer medication or have not responded to psychotherapy alone be treated with either an antidepressant or lisdexamfetamine 1
- FDA-approved specifically for moderate to severe BED in adults 22
- Maintenance treatment shows good outcomes with 59.4% remission rates and continued weight loss 3
GLP-1 Agonists:
- Emerging evidence shows moderate reductions in binge eating (g = -0.23), loss of control eating, and eating disinhibition 4
- Consistent reductions in binge eating behaviors across multiple studies, with weight loss of -3 to -24 kg 5
- Effects appear larger in patients with diagnosed BED 4
Safety Concerns with Polypharmacy
Adding amantadine to this regimen creates unnecessary risks:
- Lisdexamfetamine already carries significant warnings: abuse potential, cardiovascular risks, psychiatric effects, and requires monitoring of blood pressure and heart rate 222
- Drug interaction complexity: The patient is on a stimulant plus a GLP-1 agonist—adding a third psychoactive medication without evidence increases unpredictable interaction risks
- No complementary mechanism: Amantadine's dopaminergic effects don't address any gap in the current regimen
What to Do Instead
Optimize Current Medications First
- Ensure lisdexamfetamine is at optimal dose (50-70 mg/day for BED) 2
- Continue GLP-1 agonist at therapeutic dose for weight management
- Monitor for response over 12 weeks before considering changes 3
If Additional Treatment Is Needed
Only consider adding another agent if:
- Inadequate response after 6-12 weeks at optimal doses
- Specific comorbidities require treatment (depression, anxiety)
Evidence-based options if needed:
- Topiramate: Has evidence for BED but causes cognitive side effects 6
- SSRIs: For comorbid depression/anxiety (fluoxetine, sertraline) 6
- Cognitive-behavioral therapy: APA recommends (1C) eating disorder-focused CBT as first-line 1
Common Pitfall to Avoid
Do not add medications without evidence simply because the patient requests "more aggressive treatment." The current regimen already includes the only FDA-approved medication for BED plus an emerging therapy with growing evidence. Adding amantadine would be prescribing based on hope rather than data, exposing the patient to unnecessary risks.